Meritain Health policies

Search Meritain Health's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

66 policies name 96417, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Meritain Health policies
PolicyDetailsCodesSource
0921-Daunorubicin-Cytarabine Liposome (Vyxeos)0921 · Commercial4Original policy ↗
0960-Azacitidine0960 · Commercial4Original policy ↗
0984-Naxitamab-gqgk (Danyelza)0984 · Commercial4Original policy ↗
0891-Blinatumomab (Blincyto)0891 · Commercial5Original policy ↗
0922-Gemtuzumab Ozogamicin (Mylotarg)0922 · Commercial5Original policy ↗
0959-Pegaspargase (Oncaspar)0959 · Commercial5Original policy ↗
0985-Margetuximab-cmkb (Margenza)0985 · Commercial5Original policy ↗
0991-Fosdenopterin (Nulibry)0991 · Commercial5Original policy ↗
1005-Tebentafusp-tebn (Kimmtrak)1005 · Commercial5Original policy ↗
1025-Mosunetuzumab-axgb (Lunsumio and Lunsumio Velo)1025 · Commercial5Original policy ↗
Denileukin Diftitox-cxdl (Lymphir)1070 · Commercial5Original policy ↗
0887-Belinostat (Beleodaq)0887 · Commercial6Original policy ↗
0979-Tafasitamab-cxix (Monjuvi)0979 · Commercial6Original policy ↗
0994-Loncastuximab Tesirine-lpyl (Zynlonta)0994 · Commercial6Original policy ↗
0924-Axicabtagene Ciloleucel (Yescarta)0924 · Commercial7Original policy ↗
0986-Lisocabtagene Maraleucel (Breyanzi)0986 · Commercial7Original policy ↗
0992-Idecabtagene Vicleucel (Abecma)0992 · Commercial7Original policy ↗
1001-Sirolimus Protein-Bound Particles for Injectable Suspension Albumin-Bound (Fyarro)1001 · Commercial7Original policy ↗
Brexucabtagene Autoleucel (Tecartus)0980 · Commercial7Original policy ↗
0864-Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn (Rylaze)0864 · Commercial8Original policy ↗
1052-Exagamglogene Autotemcel (Casgevy)1052 · Commercial8Original policy ↗
0920-Tisagenlecleucel (Kymriah)0920 · Commercial9Original policy ↗
0802-Sipuleucel-T (Provenge)0802 · Commercial10Original policy ↗
0916-Avelumab (Bavencio)0916 · Commercial10Original policy ↗
0949-Caplacizumab-yhdp (Cablivi)0949 · Commercial10Original policy ↗
1019-Tremelimumab-actl (Imjudo)1019 · Commercial10Original policy ↗
1021-Mirvetuximab Soravtansine-gynx (Elahere)1021 · Commercial10Original policy ↗
0868-Decitabine0868 · Commercial11Original policy ↗
0873-Temsirolimus (Torisel)0873 · Commercial11Original policy ↗
0936-Ibalizumab-uiyk (Trogarzo)0936 · Commercial12Original policy ↗
0973-Pertuzumab Products0973 · Commercial13Original policy ↗
0981-Belantamab Mafodotin-blmf (Blenrep)0981 · Commercial13Original policy ↗
0958-Gemcitabine0958 · Commercial14Original policy ↗
0995-Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro)0995 · Commercial15Original policy ↗
1007-Ciltacabtagene Autoleucel (Carvykti)1007 · Commercial15Original policy ↗
ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP)0780 · Commercial15Original policy ↗
0834-Paclitaxel, Albumin-Bound0834 · Commercial16Original policy ↗
1006-Sutimlimab-jome (Enjaymo)1006 · Commercial17Original policy ↗
1018-Teclistamab-cqyv (Tecvayli)1018 · Commercial17Original policy ↗
0748-Panitumumab (Vectibix)0748 · Commercial18Original policy ↗
0940-Mogamulizumab-kpkc (Poteligeo)0940 · Commercial19Original policy ↗
0874-Radium Ra 223 Dichloride (Xofigo)0874 · Commercial20Original policy ↗
0902-Irinotecan Liposome Injection (Onivyde)0902 · Commercial21Original policy ↗
1026-Lecanemab-irmb (Leqembi)1026 · Commercial21Original policy ↗
0675-Bortezomib Products0675 · Commercial23Original policy ↗
1013-Spesolimab-sbzo (Spevigo)1013 · Commercial28Original policy ↗
0993-Dostarlimab-gxly (Jemperli)0993 · Commercial31Original policy ↗
0195-Erythropoesis Stimulating Agents0195 · Commercial32Original policy ↗
Voice Therapy0646 · Commercial32Original policy ↗
Pemetrexed Products0687 · Commercial35Original policy ↗

Back to Meritain Health

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.